• award and prize

Shine-On Biomedical Co., Ltd. Accorded the International Innovation Awards 2022 for TROY CAR EXOs

PRNewswire January 5, 2023

SINGAPORE, Jan. 5, 2023 /PRNewswire/ — Enterprise Asia is pleased to honor 39 remarkable innovations at the 6th International Innovation Awards (IIA) 2022. The awards took place in Bangkok, Thailand following the International Innovation Summit 2022 which convened over 300 innovation experts, industry leaders, and policymakers worldwide. As one of the pillars of the Innovation Revolution movement spearheaded by Enterprise Asia since 2017, the awards aim to create an innovation ecosystem for enterprises which is held annually to recognize outstanding innovations across the globe.

The awards drew an exceptional mix of submissions from various industries across 19 countries. 39 innovations were selected and crowned winners from over 200 applications through undergoing a rigorous evaluation process by a jury of prominent judges across three categories: Product, Service & Solution, and Organization & Culture.

Shine-On Biomedical Co., Ltd.’s Award-Winning Innovation

Shine-On Biomedical Co., Ltd.’s TROY CAR EXOs was awarded under the Product Category.

Shine-On Biomedical is deploying and engineering secreted extracellular vesicles (EV) and exosomes, taking its natural transmission advantages to develop an entirely novel class of bio-therapeutics. With a comprehensive intellectual property portfolio creation including proprietary manufacturing, purification, and preservation methods, as well as a clinical translation platform establishment, Shine-On Biomedical’s EV novel therapeutics, Troy-Exos, are engineered exosomes with a safe and potent modality for precision delivery of advanced payloads.

Troy-Exos owned a patented endogenous immune checkpoint antibody and designed a novel genetic engineering modification method to fuse on the EV’s membrane proteins. Furthermore, they are loaded with small molecules and nucleic acid drugs with high efficiency. This nano-level immune checkpoint nanobody acting as TROY CAR Exos’ target is highly-expressed outside the double-layer phospholipid layer of exosomes, which increases the specificity of exosomes to attack tumors instead of normal tissue cells. In addition, Troy-Exos with immune checkpoint nanobodies can also prohibit the inhibitory effect of immune cells caused by immune checkpoint antigens after binding to tumor cells, thus increasing the killing of tumor cells by T cells.

Ultimately, Troy-Exos presents a novel and unique concept of next-generation anticancer therapeutics. They solve the current problems of “nucleic acid therapeutics” packaging carriers in cancer treatment and benefit patients by reducing the unwanted side effects of drugs while improving the therapeutic efficacy for late-stage cancer patients and patients’ quality of life.

About Enterprise Asia

Enterprise Asia is a non-governmental organization in the pursuit of creating an Asia that is rich in entrepreneurship as an engine towards sustainable and progressive economic and social development. Please visit www.enterpriseasia.org for more information.

About International Innovation Awards

The International Innovation Awards is an annual recognition program that recognizes outstanding innovations, and in the process, encourages organizations to continue investing in innovations. For more information, visit www.innovationaward.org.

About the International Innovation Summit

The International Innovation Summit annually provides an unparalleled platform for innovators that is power packed with networking and sharing of insights with an elite community of business leaders. The summit aims to resolve major challenges in innovation structures and at the same tie search for opportunities and new ideas to drive business growth for the future. For more information, visit www.innosummit.org.

SOURCE Enterprise Asia

AAPR aggregates press releases and media statements from around the world to assist our news partners with identifying and creating timely and relevant news.

All of the press releases published on this website are third-party content and AAP was not involved in the creation of it. Read the full terms.